A

EBOV group 1

EBOV group 2

EBOV group 3

EBOV group 4

EBOV

BDBV

TAFV

SUDV

34.2

Amino acid substitutions per 100 residues

B

1st Level	EBOV G1+G2		EBOV G3+G4			
2nd Level	EBOV				BDBV/TAFV	SUDV
3rd Level	EC1					

|						
1st Level	EBOV G1	EBOV G2	EBOV G3	EBOV G4	BDBV	TAFV
2nd Level	EBOV				BDBV/TAFV	SUDV
3rd Level	EC2					

Supplemental Figure 1. Phylogenetic tree (**A**) and schematic showing the approach to create consensus sequences (**B**). The accession numbers of the sequences included in the phylogenetic analysis are as follows: Zaire95 (accession # AAB37095), Mayinga (AAC54887), deRoover (AGB56839), Bonduni (AGB56749), 13709 kikwit (AGB56821), Eckron76 (P87671), EboBund112\2012 (AGL73453), EboBund120\2012 (AGL73460), EboBund122 (AGL73467), EboBund14\2012 (AGL73474), Côte d'Ivoire (AAB37093), YP_003815435 (YP_003815435), Yambio (ABY75325), Nakisamata (AFP28231), EboSud639 (AGL50928), EboSud602 (AGL73425), EboSud603 (AGL73432), EboSud639 (AGL73439), EboSud682 (AGL73446), Maleo (AGB56678), Boniface (Q66814), Uganda\00 [Gulu] (YP_138523), Congo08KS (AER59712), AY098 (AY526098), AY099 (AY526099), AY100 (AY526100), AY101 (AY526101), AY102 (AY526102), AY105 (AY526105), EU630 (EU051630), EU631 (EU051631), EU632 (EU051632), EU634 (EU051634), EU635 (EU051635), EU636 (EU051636), EU637 (EU051637), EU638 (EU051638), 43/Luebo (KC242788), 1994/Gabon (KC242792), 1Eko (KC242793), 2Nza (KC242794), 1Oba (KC242797), 1Mbie (KC242795), 1Ikot (KC242798), Ilembe (KC242800), CODKikwit6 (KC242796), COD0Leubo (KC242785), COD1Leubo (KC242786), COD23Leubo (KC242787), COD4Leubo (KC242789), COD9Leubo (KC242784) and COD5Leubo (KC242790).

Supplemental Figure 2. Flow cytometry gating strategy for evaluation of Fc-mediated protective functions. A, antibody-dependent neutrophil phagocytosis. **B**, antibody-dependent activation of NK cells. **C**, antibody-dependent complement deposition. **D**, antibody-dependent monocyte phagocytosis. Representative flow cytometry plots of samples within the indicated vaccination groups in response to recombinant EBOV GP are shown on the right. The c13C6 mAb was used as a positive control.